GLS - Demand emerged at 375-425 in Oct-22After being in downward sloping channel from Aug'21
Plan
- Consider to Buy above 425
- and/ or Rejections near 375
Key stats
Market capitalization
48.025BINR
Dividends yield (FY)
8.04%
Price to earnings Ratio (TTM)
11.45
Basic EPS (TTM)
34.25INR
About GLENMARK LIFE SCIENCE LTD
ISIN
INE03Q201024
Sector
Health Technology
Industry
Pharmaceuticals: Major
Website
glenmarklifesciences.com
CEO
Yasir Rawjee
Headquarters
Mumbai
Employees
1.655K
Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. Its products focuses on chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes. The company was founded on June 23, 2011 and is headquartered in Mumbai, India.
WHY INVESTORS IGNORE STRONG FUNDAMENTALGLS NSE Shares:
Market Cap
₹ 5,428 Cr.
Current Price
₹ 445
High / Low
₹ 800 / 376
Stock P/E
12.8
Book Value
₹ 161
Dividend Yield
2.42 %
ROCE
96.9 %
ROE
61.0 %
Face Value
₹ 2.00
EPS
₹ 134
Industry PE
24.3
Debt
₹ 3.64 Cr.
Debt to equity
0.00
Earning Power
26.5 %
Promoter holding
82.8 %
FII holding
See all ideas
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0